SecBot SecBot
PRESS-RELEASE ·Filed Mar 23, 2026

HCM

HUTCHMED (China) Limited
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

This registrational trial represents a major step toward potential approval and commercialization of HMPL-760. Traders should monitor enrollment progress, upcoming interim data, and any future FDA/EMA trial initiation. The absence of partnership or dilution risk (HUTCHMED retains full rights) enhances equity upside.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$14.12
T+0 close · Mar 24, 2026 · via day close
Latest settled
−27.20%
T+60 · $10.28
Vs SPY
−41.52%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 24 $14.12entry
  2. T+1 · 8mo ago +0.21%α −0.34% · $14.15
  3. T+5 · 8mo ago +5.95%α +6.38% · $14.96
  4. T+20 · 7mo ago +3.12%α −5.77% · $14.56
  5. T+60 · 5mo ago −27.20%α −41.52% · $10.28
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HUTCHMED has initiated a registrational Phase III trial for HMPL-760, a third-generation BTK inhibitor, in combination with R-GemOx for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in China. The trial follows promising Phase II results showing improved response and survival outcomes, positioning HMPL-760 as a potential best-in-class therapy targeting both wild-type and C481S-mutated BTK.

Key Facts

  • HUTCHMED initiated a registrational Phase III trial of HMPL-760 in combination with R-GemOx for relapsed/refractory DLBCL in China.
  • First patient dosed on March 20, 2026; trial is randomized, double-blind, and placebo-controlled.
  • Primary endpoints are progression-free survival (PFS) and overall survival (OS); trial will enroll ~240 patients.
  • Phase II data (NCT06601504) showed improved ORR, CRR, PFS, and OS with manageable safety profile.
  • HMPL-760 is a non-covalent, reversible, third-generation BTK inhibitor active against C481S-mutated BTK, a key resistance mechanism.
  • HUTCHMED retains global rights to HMPL-760, enabling full commercial upside.

Financial Impact

High long-term value potential if approved, given DLBCL's prevalence (~81,000 new NHL cases annually in China) and lack of effective therapies for relapsed/refractory patients.

pipeline valuerevenue (long-term)R&D expense (near-term)

Risk Factors

  • Clinical trial may fail to confirm Phase II efficacy, particularly in PFS and OS endpoints.
  • Safety issues could emerge in larger trial population.
  • Regulatory delays or requirements for additional studies could prolong path to approval.

Market Snapshot

Exchange
OTC

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3260096

US Market Status

Market Closed · Opens in 6h 17m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 22, 2026